177 related articles for article (PubMed ID: 20417647)
1. In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein.
Zhang C; Kwan P; Zuo Z; Baum L
Life Sci; 2010 Jun; 86(23-24):899-905. PubMed ID: 20417647
[TBL] [Abstract][Full Text] [Related]
2. Several major antiepileptic drugs are substrates for human P-glycoprotein.
Luna-Tortós C; Fedrowitz M; Löscher W
Neuropharmacology; 2008 Dec; 55(8):1364-75. PubMed ID: 18824002
[TBL] [Abstract][Full Text] [Related]
3. Potential role for human P-glycoprotein in the transport of lacosamide.
Zhang C; Chanteux H; Zuo Z; Kwan P; Baum L
Epilepsia; 2013 Jul; 54(7):1154-60. PubMed ID: 23551115
[TBL] [Abstract][Full Text] [Related]
4. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro.
Yang HW; Liu HY; Liu X; Zhang DM; Liu YC; Liu XD; Wang GJ; Xie L
Neurosci Lett; 2008 Apr; 434(3):299-303. PubMed ID: 18313849
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro.
Yang ZH; Liu XD
Epilepsy Res; 2008 Jan; 78(1):40-9. PubMed ID: 18063342
[TBL] [Abstract][Full Text] [Related]
6. P-Glycoprotein expression in human retinal pigment epithelium cell lines.
Constable PA; Lawrenson JG; Dolman DE; Arden GB; Abbott NJ
Exp Eye Res; 2006 Jul; 83(1):24-30. PubMed ID: 16530756
[TBL] [Abstract][Full Text] [Related]
7. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
8. Assessment of antiepileptic drugs as substrates for canine P-glycoprotein.
West CL; Mealey KL
Am J Vet Res; 2007 Oct; 68(10):1106-10. PubMed ID: 17916018
[TBL] [Abstract][Full Text] [Related]
9. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats.
van Vliet EA; van Schaik R; Edelbroek PM; Voskuyl RA; Redeker S; Aronica E; Wadman WJ; Gorter JA
J Pharmacol Exp Ther; 2007 Jul; 322(1):141-7. PubMed ID: 17392402
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats.
van Vliet EA; van Schaik R; Edelbroek PM; Redeker S; Aronica E; Wadman WJ; Marchi N; Vezzani A; Gorter JA
Epilepsia; 2006 Apr; 47(4):672-80. PubMed ID: 16650133
[TBL] [Abstract][Full Text] [Related]
11. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
Zhu HJ; Wang JS; Markowitz JS; Donovan JL; Gibson BB; Gefroh HA; Devane CL
J Pharmacol Exp Ther; 2006 May; 317(2):850-7. PubMed ID: 16439618
[TBL] [Abstract][Full Text] [Related]
12. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
Baltes S; Gastens AM; Fedrowitz M; Potschka H; Kaever V; Löscher W
Neuropharmacology; 2007 Feb; 52(2):333-46. PubMed ID: 17045309
[TBL] [Abstract][Full Text] [Related]
13. Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus.
Bankstahl JP; Löscher W
Epilepsy Res; 2008 Nov; 82(1):70-85. PubMed ID: 18760905
[TBL] [Abstract][Full Text] [Related]
14. Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain.
Wen T; Liu YC; Yang HW; Liu HY; Liu XD; Wang GJ; Xie L
J Neurol Sci; 2008 Jul; 270(1-2):99-106. PubMed ID: 18440557
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
[TBL] [Abstract][Full Text] [Related]
16. Blood-brain barrier cell line PBMEC/C1-2 possesses functionally active P-glycoprotein.
Neuhaus W; Stessl M; Strizsik E; Bennani-Baiti B; Wirth M; Toegel S; Modha M; Winkler J; Gabor F; Viernstein H; Noe CR
Neurosci Lett; 2010 Jan; 469(2):224-8. PubMed ID: 19963040
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique.
Fortuna A; Alves G; Falcão A; Soares-da-Silva P
Epilepsia; 2012 Mar; 53(3):529-38. PubMed ID: 22372629
[TBL] [Abstract][Full Text] [Related]
18. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
[TBL] [Abstract][Full Text] [Related]
19. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.
Batrakova EV; Miller DW; Li S; Alakhov VY; Kabanov AV; Elmquist WF
J Pharmacol Exp Ther; 2001 Feb; 296(2):551-7. PubMed ID: 11160643
[TBL] [Abstract][Full Text] [Related]
20. In vitro transport assays of rufinamide, pregabalin, and zonisamide by human P-glycoprotein.
Chan PS; Zhang C; Zuo Z; Kwan P; Baum L
Epilepsy Res; 2014 Mar; 108(3):359-66. PubMed ID: 24530088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
